Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal preparation containing cetilistat and preparation method thereof

A pharmaceutical preparation, the technology of the new lixistat, applied in the field of medicine, can solve the problems of poor stability and slow disintegration of samples, and achieve the effects of good stability, excellent disintegration speed and excellent hardness

Inactive Publication Date: 2017-11-28
BEIJING JIMEITANG MEDICINE RES CO LTD
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Samples prepared by conventional wet granulation were slower to disintegrate and less stable

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal preparation containing cetilistat and preparation method thereof
  • Medicinal preparation containing cetilistat and preparation method thereof
  • Medicinal preparation containing cetilistat and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Tablets containing Neolistat were prepared at the composition ratios shown in Table 1 as follows.

[0029] Briefly, Neolistat, mannitol and microcrystalline cellulose were placed in a fluid bed dry granulator, and the mixture was preheated and mixed. The mixture was granulated while spraying an aqueous solution of hydroxypropyl cellulose and yellow iron oxide to obtain a granulated powder. The obtained granulated powder was passed through a 16-mesh sieve to obtain a sieved powder. To the sieved powder was added croscarmellose sodium and magnesium stearate, and the mixture was blended in a bag to obtain a blended powder. Using a rotary tablet press, using a 14×8 mm punch, the mixed powder was tableted, each tablet 240 mg.

[0030] Table 1 prescription composition

[0031]

Embodiment 2

[0033] Tablets containing Neolistat were prepared at the composition ratios shown in Table 2 as follows.

[0034] Briefly, Neolistat, mannitol and microcrystalline cellulose were placed in a fluid bed dry granulator, and the mixture was preheated and mixed. The mixture was granulated while spraying an aqueous solution of hydroxypropyl cellulose and yellow iron oxide to obtain a granulated powder. The obtained granulated powder was passed through a 16-mesh sieve to obtain a sieved powder. To the sieved powder was added croscarmellose sodium and magnesium stearate, and the mixture was blended in a bag to obtain a blended powder. Using a rotary tablet press, using a 14×8 mm punch, the mixed powder was tableted, each tablet 300 mg.

[0035] Table 2 Prescription Composition

[0036]

Embodiment 3

[0038] Tablets containing Neolistat were prepared at the composition ratios shown in Table 3 as follows.

[0039] Preparation process: Briefly, neolistat, mannitol and microcrystalline cellulose were placed in a fluidized bed dry granulator, and the mixture was preheated and mixed. The mixture was granulated while spraying an aqueous solution of hydroxypropyl cellulose and yellow iron oxide to obtain a granulated powder. The obtained granulated powder was passed through a 16-mesh sieve to obtain a sieved powder. To the sieved powder, croscarmellose sodium and magnesium fecal acid were added, and the mixture was mixed in a bag to obtain a mixed powder. Using a rotary tablet press, using a 14×8 mm punch, the mixed powder was tableted, each tablet 360 mg.

[0040] Table 3 prescription composition

[0041]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a kind of pharmaceutical preparation containing Neolistat, and this preparation is mainly made up of Neolistat, mannitol, binding agent, disintegrant and lubricant; The present invention also relates to the preparation method of this pharmaceutical preparation, adopts The new lisstat tablet prepared by the invention has the advantages of good disintegration performance, good drug stability, simple process operation and the like, and is particularly suitable for industrial production and clinical use.

Description

technical field [0001] The invention relates to a pharmaceutical preparation with neolistat as the main component and a preparation method thereof, which are used for treating obesity and its complications, and belong to the technical field of medicine. Background technique [0002] Neolistat is a long-acting and potent specific gastrointestinal lipase inhibitor, which can inhibit the activity of lipase secreted by the digestive tract and pancreas, by forming active serine sites of gastric lipase and pancreatic lipase Covalent bonds inactivate enzymes to exert therapeutic effects, prevent intestinal fat absorption and reduce body weight; at the same time, improve disease-related parameters by reducing visceral fat. The characteristics of the drug's action are that it does not act on the nervous system, does not affect other enzyme activities in the gastrointestinal tract, does not need to be absorbed through the whole body to exert its drug effect, does not suppress appetite...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/20A61K47/26A61K31/536A61P3/04
CPCA61K9/2018A61K31/536
Inventor 冯广旭
Owner BEIJING JIMEITANG MEDICINE RES CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com